NPORT-EX 2 NPORT_FJ4G_69011422_1121.htm html

Eaton Vance

Worldwide Health Sciences Fund

November 30, 2021

PORTFOLIO OF INVESTMENTS (Unaudited)

Common Stocks — 99.6%

 

                                                 
Security    Shares      Value  

Biotechnology — 10.6%

 

AbbVie, Inc.

      462,317      $ 53,295,904  

Abcam PLC(1)

      237,947        5,355,847  

Argenx SE ADR(1)

      14,886        4,156,320  

Blueprint Medicines Corp.(1)

      51,234        4,928,711  

CSL, Ltd.

      119,726        26,032,920  

Moderna, Inc.(1)

      16,712        5,889,810  

Neurocrine Biosciences, Inc.(1)

      210,577        17,530,535  

Travere Therapeutics, Inc.(1)

      121,514        3,469,225  
     

 

 

  
   $ 120,659,272  
     

 

 

  

Containers & Packaging — 0.5%

 

AptarGroup, Inc.

      44,675      $ 5,342,683  
     

 

 

  
   $ 5,342,683  
     

 

 

  

Health Care Equipment — 16.8%

 

Abbott Laboratories

      322,792      $ 40,597,550  

Boston Scientific Corp.(1)

      417,769        15,904,466  

Edwards Lifesciences Corp.(1)

      158,830        17,044,047  

Envista Holdings Corp.(1)

      311,021        12,067,615  

Fisher & Paykel Healthcare Corp., Ltd.

      306,830        6,942,199  

Inari Medical, Inc.(1)

      151,170        12,477,572  

Intuitive Surgical, Inc.(1)

      117,429        38,086,922  

Ortho Clinical Diagnostics Holdings PLC(1)

      764,172        14,626,252  

Straumann Holding AG

      4,413        9,381,805  

Tandem Diabetes Care, Inc.(1)

      99,362        12,770,004  

Teleflex, Inc.

      39,117        11,634,178  
     

 

 

  
   $ 191,532,610  
     

 

 

  

Health Care Services — 2.8%

 

Accolade, Inc.(1)

      152,078      $ 3,903,842  

Agiliti, Inc.(1)

      702,673        14,798,294  

LHC Group, Inc.(1)

      62,560        7,176,883  

R1 RCM, Inc.(1)

      275,354        6,558,932  
     

 

 

  
   $ 32,437,951  
     

 

 

  

Health Care Supplies — 3.6%

 

Alcon, Inc.

      223,253      $ 17,634,466  

Asahi Intecc Co., Ltd.

      255,800        5,606,888  

Cooper Cos., Inc. (The)

      29,764        11,205,253  

Pulmonx Corp.(1)

      186,189        6,013,905  
     

 

 

  
   $ 40,460,512  
     

 

 

  

 

1

 

 

                                                 
Security    Shares      Value  

Health Care Technology — 2.2%

 

JMDC, Inc.(1)

      150,000      $ 11,988,671  

Veeva Systems, Inc., Class A(1)

      46,863        13,242,547  
     

 

 

  
   $ 25,231,218  
     

 

 

  

Life Sciences Tools & Services — 14.6%

 

10X Genomics, Inc., Class A(1)

      49,707      $ 7,595,727  

Agilent Technologies, Inc.

      82,139        12,394,775  

Danaher Corp.

      148,874        47,883,833  

Lonza Group AG

      24,002        19,353,951  

PolyPeptide Group AG(1)(2)

      74,841        10,148,046  

Thermo Fisher Scientific, Inc.

      81,915        51,838,269  

Waters Corp.(1)

      50,487        16,563,270  
     

 

 

  
   $ 165,777,871  
     

 

 

  

Managed Health Care — 9.3%

 

Anthem, Inc.

      52,217      $ 21,212,112  

UnitedHealth Group, Inc.

      190,296        84,533,289  
     

 

 

  
   $ 105,745,401  
     

 

 

  

Pharmaceuticals — 39.2%

 

AstraZeneca PLC

      379,106      $ 41,563,193  

Bristol-Myers Squibb Co.

      453,800        24,337,294  

Dechra Pharmaceuticals PLC

      138,439        9,309,460  

Eli Lilly & Co.

      201,857        50,068,610  

Johnson & Johnson

      530,197        82,673,618  

Merck & Co., Inc.

      229,777        17,212,595  

Novartis AG

      136,602        10,887,963  

Novo Nordisk A/S, Class B

      389,197        41,663,526  

Pfizer, Inc.

      359,209        19,300,300  

Roche Holding AG PC

      159,632        62,321,954  

Royalty Pharma PLC, Class A

      320,270        12,737,138  

Sanofi

      393,094        37,368,422  

Zoetis, Inc.

      167,945        37,290,508  
     

 

 

  
   $ 446,734,581  
     

 

 

  

Total Common Stocks
(identified cost $713,087,341)

 

    $ 1,133,922,099  
     

 

 

  

Convertible Preferred Stocks — 0.2%

 

Security    Shares      Value  

Biotechnology — 0.2%

      

Caris Life Sciences, Inc., Series D(1)(3)(4)

      370,370      $ 2,699,997  
     

 

 

  

Total Convertible Preferred Stocks
(identified cost $3,000,000)

 

    $ 2,699,997  
     

 

 

  

 

2

 

 

                                                 

Short-Term Investments — 0.1%

 

Description    Units      Value  

Eaton Vance Cash Reserves Fund, LLC, 0.08%(5)

      647,231      $ 647,166  
     

 

 

  

Total Short-Term Investments
(identified cost $647,166)

 

    $ 647,166  
     

 

 

  

Total Investments — 99.9%
(identified cost $716,734,507)

 

    $ 1,137,269,262  
     

 

 

  

Other Assets, Less Liabilities — 0.1%

 

    $ 1,466,110  
     

 

 

  

Net Assets — 100.0%

 

    $ 1,138,735,372  
     

 

 

  

The percentage shown for each investment category in the Portfolio of Investments is based on net assets.

 

(1)

Non-income producing security.

 

(2)

Security exempt from registration under Rule 144A of the Securities Act of 1933, as amended. These securities may be sold in certain transactions in reliance on an exemption from registration (normally to qualified institutional buyers). At November 30, 2021, the aggregate value of these securities is $10,148,046 or 0.9% of the Fund’s net assets.

 

(3)

For fair value measurement disclosure purposes, security is categorized as Level 3.

 

(4)

Restricted security.

 

(5)

Affiliated investment company, available to Eaton Vance portfolios and funds, which invests in high quality, U.S. dollar denominated money market instruments. The rate shown is the annualized seven-day yield as of November 30, 2021.

Country Concentration of Portfolio

 

                                                 
Country   

Percentage of

Net Assets

     Value  

United States

      71.6 %    $ 814,964,539  

Switzerland

      10.5       119,580,139  

United Kingdom

      6.0       68,965,638  

Denmark

      3.7       41,663,526  

France

      3.3       37,368,422  

Australia

      2.3       26,032,920  

Japan

      1.5       17,595,559  

New Zealand

      0.6       6,942,199  

Netherlands

      0.4       4,156,320  
  

 

 

    

 

 

  

Total Investments

      99.9 %    $     1,137,269,262  
  

 

 

    

 

 

  

Abbreviations:

 

ADR

   -   American Depositary Receipt

PC

   -   Participation Certificate

The Fund did not have any open derivative instruments at November 30, 2021.

 

3

 

 

Restricted Securities

At November 30, 2021, the Fund owned the following security (representing 0.2% of net assets) which was restricted as to public resale and not registered under the Securities Act of 1933 (excluding Rule 144A securities). The Fund has limited registration rights with respect to this security. The value of restricted securities is determined based on valuations provided by brokers when available, or if not available, they are valued at fair value using methods determined in good faith by or at the direction of the Trustees.

 

                                                                                                   
Description   

Date of

Acquisition

      Shares      Cost      Value  

Convertible Preferred Stocks

            

Caris Life Sciences, Inc., Series D

      5/12/21        370,370      $ 3,000,000      $ 2,699,997  
        

 

 

     

 

 

  

Total Convertible Preferred Stocks

          $ 3,000,000      $ 2,699,997  
        

 

 

     

 

 

  

Total Restricted Securities

          $     3,000,000      $     2,699,997  
        

 

 

     

 

 

  

At November 30, 2021, the value of the Fund’s investment in affiliated funds was $647,166, which represents 0.1% of the Fund’s net assets. Transactions in affiliated funds by the Fund for the fiscal year to date ended November 30, 2021 were as follows:

 

                                                                                                                                                                                                       

Name

   Value,
beginning of
period		     Purchases     Sales
proceeds		     Net
realized
gain (loss)		     Change in
unrealized
appreciation
(depreciation)		     Value, end of
period		     Dividend
income		     Units, end
of period		  
                                                 

Short-Term Investments

 

            

Eaton Vance Cash Reserves Fund, LLC

   $     6,140,576     $     29,914,471     $     (35,407,726 )    $     (155 )    $     —     $     647,166     $     181       647,231  

Under generally accepted accounting principles for fair value measurements, a three-tier hierarchy to prioritize the assumptions, referred to as inputs, is used in valuation techniques to measure fair value. The three-tier hierarchy of inputs is summarized in the three broad levels listed below.

 

•  

Level 1 — quoted prices in active markets for identical investments

 

•  

Level 2 — other significant observable inputs (including quoted prices for similar investments, interest rates, prepayment speeds, credit risk, etc.)

 

•  

Level 3 — significant unobservable inputs (including a fund’s own assumptions in determining the fair value of investments)

In cases where the inputs used to measure fair value fall in different levels of the fair value hierarchy, the level disclosed is determined based on the lowest level input that is significant to the fair value measurement in its entirety. The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities.

At November 30, 2021, the hierarchy of inputs used in valuing the Fund’s investments, which are carried at value, were as follows:

 

Asset Description    Level 1      Level 2     Level 3*      Total  
Common Stocks

 

Biotechnology

    $ 89,270,505      $ 31,388,767     $ —      $ 120,659,272  

Containers & Packaging

     5,342,683        —       —        5,342,683  

Health Care Equipment

      175,208,606        16,324,004       —        191,532,610  

Health Care Services

      32,437,951        —       —        32,437,951  

Health Care Supplies

      17,219,158        23,241,354       —        40,460,512  

Health Care Technology

      13,242,547        11,988,671       —        25,231,218  

Life Sciences Tools & Services

      136,275,874        29,501,997       —        165,777,871  

Managed Health Care

      105,745,401        —       —        105,745,401  

Pharmaceuticals

      243,620,063        203,114,518       —        446,734,581  

Total Common Stocks

    $ 818,362,788      $ 315,559,311 **    $ —      $ 1,133,922,099  

Convertible Preferred Stocks

    $ —      $ —     $ 2,699,997      $ 2,699,997  

Short-Term Investments

      —        647,166       —        647,166  

Total Investments

    $     818,362,788      $     316,206,477     $     2,699,997      $     1,137,269,262  

 

*

None of the unobservable inputs for Level 3 assets, individually or collectively, had a material impact on the Fund.

 

**

Includes foreign equity securities whose values were adjusted to reflect market trading of comparable securities or other correlated instruments that occurred after the close of trading in their applicable foreign markets.

 

4

 

 

Level 3 investments at the beginning and/or end of the period in relation to net assets were not significant and accordingly, a reconciliation of Level 3 assets for the fiscal year to date ended November 30, 2021 is not presented.

For information on the Fund’s policy regarding the valuation of investments and other significant accounting policies, please refer to the Fund’s most recent financial statements included in its semiannual or annual report to shareholders.

 

5